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Azole Resistance in Aspergillus fumigatus
The prevalence and spread of azole resistance in 
clinical Aspergillus fumigatus isolates in the Netherlands are 
currently unknown. Therefore, we performed a prospective 
nationwide multicenter surveillance study to determine the 
effects of resistance on patient management strategies 
and public health. From June 2007 through January 2009, 
all clinical Aspergillus spp. isolates were screened for 
itraconazole resistance. In total, 2,062 isolates from 1,385 
patients were screened; the prevalence of itraconazole 
resistance in A. fumigatus in our patient cohort was 5.3% 
(range 0.8%–9.5%). Patients with a hematologic or oncologic 
disease were more likely to harbor an azole-resistant isolate 
than were other patient groups (p<0.05). Most patients 
(64.0%) from whom a resistant isolate was identifi ed were 
azole naive, and the case-fatality rate of patients with azole-
resistant invasive aspergillosis was 88.0%. Our study found 
that multiazole resistance in A. fumigatus is widespread in 
the Netherlands and is associated with a high death rate 
among patients with invasive aspergillosis.
Azoles are the primary class of antifungal agents used for evidence-based treatment and prevention of 
Aspergillus spp. diseases (1). Azoles are the only class of 
mold-active agents that can be used orally, and voriconazole 
and posaconazole have improved the survival of patients 
at risk for invasive aspergillosis (2–5). However, recent 
reports describe the emergence of acquired resistance 
of Aspergillus spp. to azole compounds (6–16). Azole 
resistance may develop in patients with cavitary lung 
lesions, such as aspergilloma, or in patients with allergic 
bronchopulmonary aspergillosis who are treated with 
mold-active azoles, most notably, itraconazole (7,17). In 
these patients, resistance is most commonly observed in 
Aspergillus fumigatus, and the isolates may be resistant to 
only itraconazole (ITZ) or exhibit a multi-azole– or pan-
azole–resistant phenotype. The phenotype depends on 
the underlying resistance mechanism, which commonly 
involves point mutations in the cyp51A-gene, the target 
for antifungal azoles (6–8,10,11,17–21). A wide range of 
mutations was found in azole-resistant Aspergillus spp. 
isolates that were cultured from clinical samples from 
patients treated with azoles, and individual azole-resistant 
Aspergillus spp. colonies harbored different resistance 
mechanisms (7).
In the Netherlands, a highly dominant resistance 
mechanism was found in isolates from epidemiologically 
unrelated patients (6,9). The dominant resistance mechanism 
consisted of a substitution of leucine for histidine at codon 
98 of the cyp51A-gene in combination with a 34-bp tandem 
repeat in the promoter region of this gene (TR/L98H) 
(6,11). The corresponding phenotype showed resistance to 
itraconazole and intermediate susceptibility or resistance 
to voriconazole, posaconazole, or both (6,20). TR/L98H 
isolates were recovered from azole-treated and azole-naive 
patients with Aspergillus spp. diseases (6,9,10,22–24). 
Azole resistance may be associated with a high probability 
of azole treatment failure, a possibility that is supported by 
preclinical evidence (7,9,22–26).
On the basis of the above-mentioned observations, 
we hypothesized that resistance might have emerged 
as a consequence of exposure of A. fumigatus to azole 
fungicides in the environment (27). Preliminary studies 
indeed showed that A. fumigatus isolates harboring TR/
L98H could be recovered from the environment (28,29). 
Furthermore, TR/L98H isolates were cross-resistant to 
certain azole fungicides (27,28).
The spread and prevalence of azole resistance in clinical 
A. fumigatus isolates are unknown. Various studies in the 
Netherlands that have analyzed Aspergillus spp. culture 
collections indicate that the prevalence ranges from 1.8% to 
12.8% (6,30,31). Obtaining insight into the spread of azole 
resistance is essential for determining the implications of 
resistance for patient management strategies and public 
health. We therefore conducted a prospective surveillance 
study in 7 university medical centers in the Netherlands.
Methods
Study Design
All Aspergillus spp. isolates cultured from clinical 
samples that were processed in the 7 university medical 
microbiology laboratories were routinely screened for the 
presence of azole resistance, irrespective of the clinical 
relevance of the culture result. The University Medical 
Centers are located in 7 different cities in the Netherlands, 
and clinical isolates were screened during a 20-month period 
(June 2007–January 2009). Patient data were recorded in a 
Web-based database. An online questionnaire was completed 
for every collected isolate. The questionnaire included 
questions about isolate characteristics (species identifi cation 
and date of isolation) and patient characteristics (age, sex, 
and underlying disease).
Screening ITZ Agar Slants
Aspergillus spp. colonies that grew in primary cultures 
were subcultured on Sabouraud agar slants supplemented 
with 4 mg/L of ITZ and incubated at 35°C–37°C. The 
colonies’ ability to grow on the ITZ agar slants was 
assessed after 48 hours of incubation. For every isolate that 
was able to grow on the ITZ agar slants (ITZ positive), the 
primary culture isolate was sent to the Radboud University 
Nijmegen Medical Center for further analysis. Isolates that 
failed to grow on the ITZ agar slants (ITZ negative) were 
not analyzed. However, for all isolates that were screened, 
the online questionnaire was completed. At the screening 
sites, the Aspergillus spp. isolates were identifi ed to species 
level by conventional methods, i.e., thermotolerance and 
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macroscopic and microscopic assessment of culture 
morphologic features.
Profi ciency Testing
The ITZ agar slants were prepared at the Radboud 
University Nijmegen Medical Center and distributed to 
the other medical microbiology laboratories. Each center 
was provided with a protocol and a set of 6 A. fumigatus 
isolates. Four isolates were resistant to ITZ (MIC >16 
mg/L), while 2 were susceptible (ITZ MICs 0.125 and 0.25 
mg/L). The centers were blinded for the resistance profi les 
and were asked to determine the ability of the isolates to 
grow on the ITZ agar slants.
Analysis of ITZ-positive Isolates
Every ITZ-positive isolate was analyzed for certain 
phenotypic and genotypic features. The phenotypic 
analysis included the morphologic features of the isolate 
and susceptibility testing according to established 
standards (32) by using a broth microdilution format. MICs 
were determined for ITZ, voriconazole, and posaconazole. 
Genotypic analyses were performed by complete 
sequencing of the cyp51A gene by using the reference 
sequence of strain no. AF338659 from GenBank.
For the confi rmed ITZ-positive isolates, additional 
patient data that included azole exposure <3 months 
before the date of isolation of the resistant isolate and the 
presence of Aspergillus spp. disease were requested from 
the treating physician. Patients with cancer and invasive 
aspergillosis were classifi ed according to the revised 
European Organization for Research and Treatment of 
Cancer/Mycoses Study Group defi nitions (33). In addition, 
patient data were collected on treatment and outcome 3 
months after diagnosis.
Statistical Analysis
Statistical analyses were performed by using SPSS 
version 17.0 (IBM, Somers, NY, USA). Analyses consisted 
of χ2 tests and a calculation of the κ coeffi cient.
Results
Profi ciency Testing
Four of 6 control A. fumigatus isolates were resistant to 
ITZ and expected to grow on the ITZ agar slants, while the 
remaining 2 isolates were ITZ susceptible and should not 
grow on the ITZ agar slants. The 4 isolates with the azole-
resistant phenotype harbored the TR/L98H resistance 
mechanism. For 3 ITZ-positive and the 2 ITZ-negative 
isolates, 100% agreement was found between the 7 centers. 
For 1 ITZ-positive isolate, the assessment of growth on the 
ITZ agar slant was incorrect from 3 centers; this isolate was 
a slowly sporulating A. fumigatus isolate. The κ coeffi cient 
calculated to assess the reproducibility of the method was 
0.81 (34).
Mycology
During June 2007 through January 2009, we screened 
2,062 Aspergillus spp. isolates from 1,385 patients for 
azole resistance using the ITZ agar slants. Most isolates 
were identifi ed as A. fumigatus (1,792/2,062 [86.9%]) 
(Table 1). For 50 (2.5%) Aspergillus spp. isolates, species 
identifi cation was not done. Most Aspergillus spp. isolates 
were isolated from respiratory samples; 1,461 of 2,062 
(70.9%) were from sputum cultures, and 60 (2.9%) were 
from cultures derived from clinical specimens obtained 
from sterile sites (i.e., tissue specimens obtained through 
invasive procedures or at autopsy) (Table 1).
Ninety isolates were able to grow on the ITZ agar 
slants and were sent to the Radboud University Nijmegen 
Medical Center for further analyses. In vitro susceptibility 
testing showed that for 84 (93.3%) of 90 ITZ-positive 
isolates, the MIC of ITZ was >2 mg/L, which was 
considered resistant (20). Most ITZ-positive isolates 
also exhibited non–wild-type susceptibility profi les to 
voriconazole and posaconazole. A resistant phenotype 
for voriconazole (>2 mg/L) and posaconazole (>0.5 
mg/L) was observed in 67/84 (79.8%) and 14/84 (16.7%) 
of ITZ-positive isolates, respectively. An intermediate 
susceptibility profi le (2 mg/L for voriconazole and 0.5 
mg/L for posaconazole) was observed in 12/84 (14.3%) 
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Table 1. Characteristics of screened susceptible and resistant 
isolates of Aspergillus spp., the Netherlands, 2007–2009* 
Source and species 
No. (%) susceptible, 
n = 1,978 
No. (%) resistant,
n = 84 
Specimen source 
 Sputum 1,397 (70.6) 64 (76.2) 
 Ear swab 176 (8.9) 3 (3.6) 
 BAL fluid 97 (4.9) 6 (7.1) 
 Bronchus secretion 66 (3.3) 2 (2.4) 
 Throat/nasal swab 66 (3.3) 1 (1.2) 
 Tissue 55 (2.8) 5 (6.0) 
 Skin swab/nail 38 (1.9) 1 (1.2) 
 Mouth wash 26 (1.3) 1 (1.2) 
 Pus/wound swab 16 (0.8) 1 (1.2) 
 Bronchial wash 11 (0.6) 0
 Feces 8 (0.4) 0
 Unknown 22 (1.1) 0
Species
 A. fumigatus 1,710 (86.5) 82 (97.6) 
 A. flavus 98 (5.0) 0
 A. niger 52 (2.6) 2 (2.4) 
 A. terreus 35 (1.8) 0
 A. nidulans 14 (0.7) 0
 A. versicolor 13 (0.7) 0
 A. glaucus 6 (0.3) 0
 Unknown 50 (2.5) 0
*BAL, bronchoalveolar lavage. 
Azole Resistance in Aspergillus fumigatus
and 44/84 (52.4%) of ITZ-positive isolates, respectively 
(Table 2) (20).
Sequence-based identifi cation classifi ed 82 ITZ-
positive isolates as A. fumigatus and 2 as A. niger. 
Sequencing of the cyp51A gene showed a substitution of 
leucine for histidine at codon 98 in combination with a 34-
bp tandem repeat in the gene promoter in 74 (90.2%) of 
82 resistant A. fumigatus isolates (Table 2). Other cyp51A 
mutations were found in 3 isolates (substitutions G54W, 
P216L, and F219I) (Table 2) (7,8,20,21). In 1 isolate, 
a series of mutations was found, and in the remaining 4 
azole-resistant A. fumigatus isolates (4.9%), no mutations 
were found in the cyp51A gene (8). Because A. niger has 
no known resistance mechanisms, the 2 azole-resistant A. 
niger isolates were not further analyzed.
Prevalence of Azole Resistance
A median of 100 isolates were screened each month, 
with a range of 78–140 isolates per month. The total 
number of screened clinical isolates per center ranged 
from 130 to 449 and were recovered from 84 to 238 
patients. The collection of isolates over the study period 
and the distribution of the recovery of resistant isolates are 
shown in Figure 1. Overall, 82 (4.6%) of 1,792 screened 
A. fumigatus isolates were azole resistant. The per-patient 
analysis showed a prevalence of 5.3%. Figure 2 shows the 
prevalence of resistance in A. fumigatus per center. The 
prevalence of azole resistance in A. niger was 3.8%. No 
seasonal variation was observed.
Patient Characteristics
The screened A. fumigatus isolates were cultured from 
1,192 patients, while other Aspergillus spp. isolates were 
recovered from 193 patients. Among the patients who 
harbored A. fumigatus isolates, the predominant underlying 
diseases were cystic fi brosis (382/1,192 [32.1%]) and other 
pulmonary diseases (265/1,192 [22.2%]) Almost 12% 
(138/1,192) of the A. fumigatus isolates were from patients 
who had hematologic/oncologic diseases. The distribution 
of underlying diseases is shown in Table 3.
Characteristics of Patients with 
Azole-Resistant Isolates
The 82 confi rmed ITZ-resistant A. fumigatus isolates 
were recovered from 63 patients. The patients’ ages ranged 
from 1 to 85 years, with a mean age of 48.9 years. The sex 
distribution was equal.
Overall, the distribution of underlying diseases in 
patients with an ITZ-resistant isolate was similar to that 
observed in the group with ITZ-susceptible isolates, with 
1 exception. In the group of patients with ITZ-resistant 
isolates, signifi cantly more patients had hematologic/
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Table 2. Characteristics of itraconazole-positive Aspergillus fumigatus isolates, the Netherlands, 2007–2009* 
No. isolates Mutations in the Cyp51A gene 
Median MIC, mg/L (range) 
Itraconazole Voriconazole Posaconazole
74 TR/L98H† >16 (16–>16) 8 (1–16) 0.5 (0.25–2) 
1 G54W† >16 0.5 >16
1 P216L† 16 2 0.5
1 F219I† >16 0.25 0.25
1 Series‡ >16 >16 1
4 None >16 (16–>16) 4 (0.5–4) 0.2 (0.125–1) 
*In vitro susceptibility testing was performed according to the Clinical and Laboratory Standards Institute M38A2 method (32).
†Mutations that have previously been shown to be associated with azole resistance in A. fumigatus (7,20,21).
‡Series of mutations in Cyp51A-gene: F46Y, G89G, M172V, N248T, D255E, L358L, E427K, and C454C (8).
Figure 1. Number of screened Aspergillus spp. 
isolates per month (bars) and prevalence (%) of 
azole resistance (line), the Netherlands, 2007–
2009. ITZ, itraconazole.
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oncologic diseases than in the group that harbored ITZ-
susceptible isolates (13/63 [20.6%] and 125/1,129 [11.1%], 
respectively; p<0.05; Table 3).
Aspergillus disease caused by an ITZ-resistant isolate 
was diagnosed in 23 patients (36%). Invasive aspergillosis 
was diagnosed in 8 patients (13%), 6 with confi rmed and 
2 with probable cases (Table 4). Four of these patients 
were azole naive, and 1 patient had been previously treated 
with fl uconazole, which has no activity against Aspergillus 
species. All A. fumigatus isolates from patients with azole-
resistant invasive aspergillosis harbored the TR/L98H 
resistance mechanism (Table 4). All 5 patients who were 
treated with voriconazole monotherapy died within 3 
months of receiving a positive culture result. For 3 patients, 
voriconazole therapy was switched to another class of 
antifungal compounds, i.e., echinocandin, polyene, or both, 
but only 1 of those 3 patients survived. Overall, 7 (87.5%) 
of 8 patients with azole-resistant aspergillosis died within 
3 months (Table 4).
Noninvasive Aspergillus spp. disease with an ITZ-
resistant isolate was diagnosed in 15 patients. Five 
patients had cystic fi brosis and allergic bronchopulmonary 
aspergillosis. Six patients had an aspergilloma; of these 
patients, 2 were immunocompromised, 1 because of AIDS 
and 1 because of Job syndrome. Three patients sought 
treatment for otomycosis; 1 patient had Aspergillus spp. 
sinusitis. Data on previous exposure to azoles were available 
for 14 patients with noninvasive Aspergillus spp. disease; 
and 9 (64.2%) of these patients were azole naive. The TR/
L98H mutation was the dominant resistance mechanism, 
because it was present in 12 (80%) of 15 isolates. Overall, 
14 (64.3%) of 22 patients with azole-resistant Aspergillus 
spp. disease and known status of azole exposure were azole 
naive at the time the resistant isolate was cultured.
Discussion
Azole resistance is widespread in clinical A. fumigatus 
isolates in the Netherlands, and resistant isolates were 
found at all participating university medical centers. The 
overall prevalence was 5.3%, which is in a similar range as 
observed in the fungus culture collection of the Radboud 
University Nijmegen Medical Center (6). However, the 
prevalence varied widely between the centers, with 1 center 
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Figure 2. Prevalence (%) of azole-resistant Aspergillus fumigatus 
infections in university medical centers, the Netherlands, 2007–
2009.
Table 3. Underlying diseases of patients from whom azole-susceptible and -resistant Aspergillus fumigatus isolates were recovered, 
the Netherlands, 2007–2009 
Underlying condition 
No. (%) patients with 
susceptible isolates, n = 1,129 
No. (%) patients with 
resistant isolates, n = 63 p value* 
Cystic fibrosis 365 (32.3) 17 (27.0) 0.38
Pulmonary disease, excluding cystic fibrosis  251 (22.2) 14 (22.2) 1.00
Hematologic/oncologic disease 125 (11.1) 13 (20.6) 0.02
Otorhinolaryngologic disease 63 (5.6) 3 (4.8) 0.78
Internal disease 85 (7.5) 8 (12.7) 0.14
Solid organ transplantation 26 (2.3) 2 (3.2) 0.66
Intensive care unit patient 31 (2.7) 2 (3.2) 0.84
Cardiac disease 9 (0.8) 1 (1.6) 0.50
Chronic granulomatous disease 5 (0.4) 0 0.60
Postoperative condition 23 (2.0) 1 (1.6) 0.81
Neurologic disease 2 (0.2) 0 0.74
Disease in children, not specified 4 (0.4) 0 0.64
Dermatologic disease 6 (0.5) 1 (1.6) 0.29
Other 91 (8.1) 1 (1.6) 
Unknown 43 (3.8) 0
*F2 test. 
Azole Resistance in Aspergillus fumigatus
showing azole resistance in 10 (9.5%) of 105 patients with 
a positive Aspergillus spp. culture. In a previous study, 
we reported a resistance prevalence of 12.8% among A. 
fumigatus isolates sent to our department by other hospitals 
in the Netherlands (6). This higher resistance rate may have 
been due to a different selection of isolates. In this study, 
all Aspergillus spp. isolates cultured in the participating 
laboratories were screened for resistance, irrespective of 
their clinical relevance, while in our previous study the 
isolates that were sent to Nijmegen were from patients with 
Aspergillus spp. diseases for whom antifungal therapy was 
not successful (6).
Two other studies have investigated the prevalence of 
azole resistance in Aspergillus spp. in the Netherlands. One 
study investigated a collection of 170 clinical A. fumigatus 
isolates recovered from 114 patients from 21 different 
medical centers in 1945–1998 (30). Three (1.8%) isolates 
were resistant to ITZ and were later found to harbor the TR/
L98H resistance mechanism. These were the fi rst TR/L98H 
isolates recovered in the Netherlands (6). Another study 
investigated the prevalence of azole-resistant Aspergillus 
spp. isolates in the Netherlands by using a collection of 209 
unselected clinical A. fumigatus isolates obtained over a 
6-month period in 2005 (31). Only 4 azole-resistant isolates 
were found, which corresponds with a prevalence of 1.9% 
(31). The low prevalence may be because of the methods 
used. We used ITZ-containing agar-slants to select for 
resistant isolates, which enables detection of resistant 
colonies even in the presence of multiple azole-susceptible 
colonies. Although Klaassen et al. (31) did not explain how 
isolates were obtained, azole-resistant colonies could have 
been missed if regular culture media were used (22,31). 
A κ coeffi cient of 0.81 indicates that screening for azole 
resistance by using agar supplemented with ITZ is a highly 
reproducible method and appears to be a feasible approach 
for screening for azole resistance and for surveillance 
studies (34).
Most (74/82 [90.2%]) of the azole-resistant isolates 
in our study were found to possess the TR/L98H mutation 
in the cyp51A-gene, which is a similar proportion as 
reported previously (6). Previous studies have suggested 
that the probability of 2 genomic changes developing 
during azole therapy is highly unlikely and that exposure 
of A. fumigatus to azoles in the environment may be a 
possible route of resistance development (6,27,28). A. 
fumigatus isolates harboring the TR/L98H resistance 
mechanism were recovered from the environment and were 
genetically related to TR/L98H-containing clinical isolates 
(28). This mode of resistance development implies that 
previous exposure of patients to azole compounds is not a 
prerequisite. Indeed, our study shows that 64% of patients 
with an azole-resistant isolate have no history of previous 
azole exposure during the 3 months before culturing the 
isolate. This fi nding supports the proposed environmental 
route of resistance development.
The prevalence and spread of TR/L98H in A. fumigatus 
in other countries are largely unknown. A recent study 
by Mortensen et al. showed that 8% of environmental A. 
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Table 4. Characteristics of patients with azole-resistant invasive aspergillosis, the Netherlands, 2007–2009* 
Patient
age, y/ 
sex Underlying disease Disease
No.
positive
cultures†
Resistance
mechanism
VCZ
MIC,
mg/L
Prior azole 
treatment
(duration)‡ Treatment§
Outcome
at 12 wk 
66/M Lung carcinoma Proven pulmonary 
aspergillosis 
1 TR/L98H 4 None VCZ Died
59/M Hematologic
malignancy, allo-SCT, 
GvHD 
Proven pulmonary 
aspergillosis 
4 TR/L98H 8 VCZ (>1 mo) VCZ Died
54/M Acute myeloid leukemia, 
relapse, allo-HSCT 
Proven pulmonary 
aspergillosis 
1 TR/L98H 8 ITZ (2–4 wk) VCZ Died
50/M Non-Hodgkin lymphoma, 
allo-SCT, GvHD, lung 
cavities 
Probable pulmonary 
aspergillosis 
2 TR/L98H 16 VCZ (>1 mo) VCZ Died
36/F Breast carcinoma with 
metastasis 
Probable pulmonary 
aspergillosis 
1 TR/L98H 1 None VCZ Died
13/F Non-Hodgkin lymphoma Proven pulmonary and 
CNS aspergillosis 
1 TR/L98H 16 None VCZ, CAS, 
AMB
Died
58/M Liver transplantation for 
hepatic failure after 
methotrexate treatment 
for arteritis 
Proven pulmonary and 
CNS aspergillosis 
5 TR/L98H 2 None AMB, VCZ Died
60/M Acute myeloid leukemia, 
allo-SCT, GvHD 
Proven pulmonary and 
CNS aspergillosis 
3 TR/L98H 4 FCZ (1–2 wk) VCZ, CAS, 
AMB, POS
Survived
*VCZ, voriconazole; allo-SCT, allogeneic hematopoietic stem cell transplantation; GvHD, graft-versus-host disease; HSCT, hematopoietic stem cell 
transplantation; ITZ, itraconazole; CNS, central nervous system; CAS, caspofungin; AMB, amphotericin B; FCZ, fluconazole; POS, posaconazole. 
† All cultures were Aspergillus fumigatus.
‡Azole treatment <12 wk before the first culturing of an azole-resistant isolate. 
§Azole treatment after first culturing of resistant isolate.  
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fumigatus isolates in Denmark harbored the TR/L98H 
resistance mechanism, which indicates that TR/L98H may 
be spreading (29). Because in vitro susceptibility testing of 
A. fumigatus is not routinely performed in most laboratories, 
international surveillance studies are warranted.
Most TR/L98H isolates were resistant to voriconazole 
(79%), but a broad range of MICs was observed that varied 
from 1 mg/L to 16 mg/L. Reasons for this variation remain 
unclear. TR/L98H isolates may have developed additional 
mutations that confer voriconazole resistance but that are 
not associated with the cyp51A gene. Another possibility 
is that the tandem repeat, which serves as a transcriptional 
enhancer, causes varying levels of up-regulation of the 
cyp51A gene. This up-regulation may result in differences 
in the voriconazole phenotype. More research is needed to 
gain insight into this phenomenon.
The outcome for patients with azole-resistant invasive 
aspergillosis was dismal, with a mortality rate of 88%. 
None of the patients who were treated with voriconazole 
monotherapy were alive at 3 months; of 3 patients whose 
treatment was switched to another class of antifungal drugs, 
only 1 survived. A critical issue for future study is whether 
azole resistance is a determinant of the poor clinical 
outcome of patients with azole-resistant aspergillosis. A 
previously reported case series of patients with primarily 
noninvasive Aspergillus spp. disease indicated that azole 
resistance was associated with treatment failure (7). 
However, establishing a relation between resistance and 
treatment outcome in invasive aspergillosis is complex 
because of the multiple factors that contribute to treatment 
outcome, including underlying disease, drug exposure, 
timing and accuracy of diagnosis, and timing of antifungal 
therapy. Furthermore, data are lacking on the effects of 
in vitro susceptibility patterns of Aspergillus spp. isolates 
on treatment outcomes. This relationship was recently 
described by using Aspergillus spp. isolates recovered from 
patients enrolled in the Transplant-Associated Infection 
Surveillance Network (35). The 12-week mortality rate 
for patients with culture-positive confi rmed or probable 
invasive aspergillosis was 53% (35). For patients with 
azole-susceptible A. fumigatus aspergillosis treated with 
voriconazole, the proportion of deaths was 48% (J.W. 
Baddley, pers. comm.).
In a study by Herbrecht et al. (2), a subset of 51 
modifi ed-intent-to-treat patients with defi nite (43 patients) 
or probable (8 patients) invasive aspergillosis had a positive 
culture with A. fumigatus with a wild-type susceptibility. 
The all-cause proportion of deaths in this group at 12 weeks 
was 39% (P. Troke, pers. comm.). Both these analyses 
show a lower death rate than observed in our study, which 
indicates that azole resistance may be associated with a 
poor outcome. The median MIC of voriconazole in the 8 
patients with azole-resistant invasive aspergillosis was 
4 mg/L, which is resistant (20). Effects of an elevated 
voriconazole MIC on treatment outcome were supported 
by preclinical experimental results, in which mice infected 
with an A. fumigatus isolate that had a voriconazole MIC 
of 2 mg/L required a 2-fold higher voriconazole dose than 
did mice infected with a wild-type isolate to achieve a 
comparable survival rate (25). 
The low survival rate of patients whose treatment was 
switched from azole therapy to nonazole therapy could be 
due to the delay of initiation of treatment with an effective 
alternative drug or to the presence of cerebral disease. 
Overall, the number of patients with azole-resistant 
aspergillosis in our study was low, and additional studies 
are needed to confi rm the relation between azole resistance 
and treatment failure. 
Because specimens from patients with invasive 
aspergillosis seldom produce positive cultures, our study 
underestimates the number of azole-resistant cases. 
The diagnosis of azole resistance in culture-negative 
cases is a challenge because current biomarkers, such as 
galactomannan and 1,3-β-D-glucan, do not enable species 
identifi cation, let alone in vitro susceptibility testing. 
Molecular tools have been shown to be able to detect 
mutations associated with azole resistance directly in tissue 
(36) or in respiratory specimens (37) but are not yet suitable 
for use in routine patient care. Molecular tools need to 
be developed that enable the rapid detection of multiple 
mutations, although only known mutations can be detected.
Our study shows that azole resistance in clinical A. 
fumigatus isolates is widespread in the Netherlands and that 
the survival rate of patients with azole-resistant invasive 
aspergillosis is low. The dominance of the TR/L98H 
resistance mechanism and the high proportion of resistant 
isolates recovered from azole-naive patients support an 
environmental route of resistance development. We believe 
that continued surveillance is required in the Netherlands, 
as well as routine in vitro susceptibility testing of A. 
fumigatus isolates obtained from patients with Aspergillus 
spp. disease. International surveillance programs are also 
warranted to estimate the size of the emerging problem 
of azole resistance. Furthermore, the fi rst-line therapy of 
patients with invasive aspergillosis should be reconsidered, 
at least in those centers with a high prevalence of azole 
resistance.
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